Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCA Healthcare, Inc. (NYSE: HCA) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HCA Healthcare is a Nashville-based provider of healthcare services with 191 hospitals and approximately 2,500 ambulatory sites of care, and its filings offer detail on how it finances and governs this network, as well as how it reports operating results to shareholders.
For this issuer, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for information on the performance of its general medical and surgical hospitals and related ambulatory facilities. These filings typically include discussions of segment operations, risk factors relevant to healthcare services, and descriptions of the company’s learning health system approach. On Stock Titan, AI-powered summaries can help explain key sections of lengthy 10-K and 10-Q documents in more accessible language.
HCA Healthcare also uses Form 8-K to report material events. Recent 8-Ks have described items such as the public offering of senior notes by HCA Inc., the company’s direct, wholly owned subsidiary, including the terms of the notes, related indentures and covenants, and the planned redemption of existing senior notes. Other 8-K filings have announced quarterly results, cash dividend declarations on HCA common stock, and changes in the Board of Directors.
Debt investors may focus on filings that describe senior notes, indentures and guarantees, including covenants that limit liens, sale and lease-back transactions, or major corporate reorganizations. Equity investors may review proxy materials and compensation disclosures, along with periodic reports, to understand governance structures and board committee responsibilities, such as the Audit and Compliance Committee and the Patient Safety and Quality of Care Committee.
Through Stock Titan, users can view real-time updates from EDGAR, see insider-related forms such as Form 4 when available, and rely on AI-generated highlights to quickly identify notable changes, obligations and events in HCA Healthcare’s SEC reporting history.
A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.
The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.
HCA Healthcare insider Thomas F. Frist Jr. reported an internal reorganization of his indirect holdings. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
After the exchange, Frisco Holding II holds 36,557,141 HCA shares, and Hercules Holding II holds 32,282,889 shares. Frist may be deemed to have voting and investment control over these entities but disclaims beneficial ownership except for his pecuniary interests, which are tied to specified partnership units and trusts.
HCA Healthcare director and 10% owner William R. Frist reported complex internal equity moves involving investment entities tied to his family. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a tax-related reorganization treated as a partnership conversion and Section 368(a) reorganization.
After the transactions, Frisco Holding II holds 36,557,141 HCA shares and Hercules Holding II holds 32,282,889 shares, with additional indirect holdings through trusts, family partnerships, and family members. Frist may be deemed to have voting and investment control over these entities but formally disclaims beneficial ownership beyond his economic interests. His direct holding of 12,931 shares includes restricted share units payable in 12,875 shares when he leaves the board.
HCA Healthcare director and 10% owner Thomas F. Frist III reported an internal share reorganization involving entities linked to him. On February 6, 2026, Frisco Holding II disposed of 36,629,188 HCA common shares in exchange for 36,557,141 newly issued shares from HCA in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
Frisco Holding II now holds 36,557,141 shares for a private investor group that includes affiliates of HCA founder Dr. Thomas F. Frist Jr. Frist III may be deemed to have voting and investment control but disclaims beneficial ownership beyond his economic interest through partnership units and related trusts. Separately, Hercules Holding II holds 32,282,889 HCA shares for a similar investor group, with Frist III likewise only recognizing his pecuniary interest. He also directly holds 14,817 restricted share units that will settle in HCA shares when he ceases to be a director.
HCA Healthcare insider-related entities completed a large internal share reorganization. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA common shares for 36,557,141 newly issued shares in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
After these transactions, Frisco Holding II holds 36,557,141 HCA shares, and Hercules Holding II holds 32,282,889 shares, with additional smaller indirect holdings through joint, spouse, and children’s trusts. The reporting person may be deemed to have voting and investment control through these entities but disclaims beneficial ownership beyond her pecuniary interests.
HCA Healthcare’s Form 4 shows that major shareholder Hercules Holding II, a 10% owner, made a large internal share distribution. On February 6, 2026, Hercules Holding II distributed 36,629,188 shares of HCA common stock for no consideration, on a pro rata basis, to Frisco Holding II. After this non-cash, reallocation-type transaction, Hercules Holding II directly held 32,282,889 HCA shares. The filing notes that Hercules Holding II is held by a private investor group that includes affiliates of HCA founder Dr. Thomas F. Frist Jr., highlighting that this is a movement of shares within an affiliated investor structure rather than an open-market sale.
Frisco Holding II, a 10% owner of HCA Healthcare, Inc., reported a restructuring of its holdings rather than an open-market trade. On February 6, 2026, it disposed of 36,629,188 common shares in exchange for 36,557,141 newly issued HCA shares.
The transactions were reported under code J and occurred at a stated price of zero per share, in a manner exempt under Rule 16b-3. Footnotes describe the steps as part of a tax-related reorganization and a change in the form of beneficial ownership without changing Frisco Holding II’s pecuniary interest.
HCA Healthcare’s largest founding shareholders have updated how they hold their stake and confirmed significant ongoing ownership. Entities and family members associated with Dr. Thomas F. Frist, Jr. report beneficial ownership figures of up to 70,555,590 shares, or 31.6% of HCA’s common stock.
On February 6, 2026, Frisco exchanged 36,629,188 existing shares with HCA for 36,557,141 newly issued shares in a transaction treated as a tax-free reorganization, and Frisco converted into a partnership. Frisco now directly owns 36,557,141 shares, or 16.3% of the 223,622,200 shares outstanding as of January 31, 2026, while Hercules directly owns 32,282,889 shares, or 14.4%.
The Frist family and affiliated entities may be deemed to share voting and investment control over these holdings and retain rights under a stockholders’ agreement to nominate up to two HCA directors. A registration rights agreement also permits, under certain conditions, registration of shares for resale, while Frisco’s sales are restricted for a defined period.
HCA Healthcare, Inc. filed its annual report describing a large, diversified hospital and outpatient network and how it generates revenue. As of December 31, 2025, HCA operated 190 hospitals, 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 U.S. states and England, with 50,436 licensed beds and 2,297,065 admissions.
For 2025, HCA reported $75.6 billion in revenues, with managed care and other insurers contributing $36.968 billion, Medicare $11.273 billion, Managed Medicare $13.435 billion, Medicaid and Managed Medicaid $9.602 billion, international payers $1.864 billion and other sources $2.458 billion. Outpatient revenues represented 38% of patient revenues. Operating metrics showed a 73% occupancy rate, 9.95 million emergency room visits, 1.02 million outpatient surgeries and 545,405 inpatient surgeries.
The report highlights a strategy focused on expanding in existing markets, enhancing clinical quality and digital and AI capabilities, and building comprehensive local networks. It also outlines extensive regulatory and reimbursement frameworks, including detailed Medicare, Medicaid, managed care and value-based payment models, as well as key risk factors such as significant indebtedness, workforce shortages, cybersecurity threats, evolving public health crises, shifting government policies, Medicaid reforms and intense competition from other hospitals, physician-owned facilities and not-for-profit systems.
HCA Healthcare SVP & Controller Christopher F. Wyatt reported equity transactions involving company stock. On February 5, 2026, he exercised 10,670 Stock Appreciation Rights at an exercise price of $139.06, receiving the same number of HCA common shares and bringing his direct holdings to 51,737 shares.
On the same date, a separate transaction coded "F" disposed of 5,674 common shares at a reported price of $513.76 per share, leaving Wyatt with 46,063 HCA common shares held directly. The underlying stock appreciation rights, which vested in four equal annual installments beginning January 30, 2020, are now fully exercised.
FAQ
What is the current stock price of Hca Healthcare (HCA)?
What is the market cap of Hca Healthcare (HCA)?
